Mapping 340B Funds Flow Through Contract Pharmacies

The 340B Drug Pricing Program, established in 1992, was designed to help safety-net healthcare providers stretch scarce resources by allowing them to purchase outpatient medications at significant discounts. However, the program's dramatic expansion, particularly following the Affordable Care Act, and the rise of contract pharmacy arrangements have led to increasing scrutiny regarding its current function and impact. This study examines the flow of funds within the modern 340B ecosystem, with a particular focus on contract pharmacies, pharmacy benefit managers (PBMs), third-party administrators (TPAs), and vertically integrated health systems. Using a detailed mapping of financial transactions, the analysis identifies key areas where profit incentives diverge from the program's original intent. Covered entities (CEs) often generate substantial profits by purchasing drugs at 340B-discounted rates and receiving standard reimbursements from public and private payers, including Medicare and commercial insurers. These profits are not required to be reinvested in care for underserved populations. Additionally, the use of contract pharmacies and TPAs has introduced significant complexity, increasing the risks of drug diversion and duplicate discounts, particularly with Medicaid and Medicare rebate programs. Vertically integrated PBM pharmacy chains dominate the landscape, often capturing outsized revenue. Legal and regulatory ambiguities further complicate oversight and enforcement. This paper provides an overview of the current 340B funds flow through contract pharmacies, highlighting areas of misalignment with the program's mission. In doing so, it informs ongoing legislative and administrative reform efforts, emphasizing the need to re-center the program around its intended beneficiaries, low-income and vulnerable patients.